Market Cap 506.25M
Revenue (ttm) 35.28M
Net Income (ttm) -169.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.11%
Debt to Equity Ratio 0.02
Volume 211,800
Avg Vol 314,810
Day's Range N/A - N/A
Shares Out 69.25M
Stochastic %K 1%
Beta 1.46
Analysts Strong Sell
Price Target $26.27

Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 1223 261 503
Address:
Portway Building, Blocks A & B Granta Park Great Abington, Cambridge, United Kingdom
kclan
kclan Jun. 24 at 4:51 PM
$BCYC get the bike off the shoulder and start making some miles!
0 · Reply
SmartestMoney
SmartestMoney Jun. 18 at 6:56 PM
0 · Reply
50bps
50bps Jun. 18 at 6:56 PM
0 · Reply
Strangperson
Strangperson Jun. 18 at 4:12 PM
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 16 at 6:58 PM
$SPRB i'm posting this here and here only $BCYC negative EV a whole bunch of programs (check their website) baker brothers bought in at much higher prices felix baker taking over as chairman today do your own research I added today
5 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 11 at 7:23 PM
$BCYC still a chance to buy under 9 anyone interested ?
1 · Reply
SmartestMoney
SmartestMoney Jun. 11 at 3:20 PM
$BCYC Do it
1 · Reply
SmartestMoney
SmartestMoney Jun. 6 at 2:50 PM
$BCYC 👁️👁️
0 · Reply
50bps
50bps Jun. 6 at 2:46 PM
$BCYC gettign tight. ht @SmartestMoney
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 4 at 3:35 PM
$BCYC Am I the only one who thinks there is a TON of hidden value here at 8 dollars and change the market for this name is very thin, but it just makes the current trading price almost meaningless Bakers and others are in much higher a piece of good news could have this 100% up inside of a day
0 · Reply
Latest News on BCYC
Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 20, 2024, 7:37 AM EDT - 11 months ago

Bicycle Therapeutics Is Looking Increasingly Attractive


2 More Potential Biotech Buyout Targets

Mar 25, 2024, 1:07 PM EDT - 1 year ago

2 More Potential Biotech Buyout Targets

AZN BMY EXEL LLY MRK NVS TAK


Bicycle Therapeutics to Host R&D Day on December 14

Nov 30, 2023, 7:00 AM EST - 1 year ago

Bicycle Therapeutics to Host R&D Day on December 14


kclan
kclan Jun. 24 at 4:51 PM
$BCYC get the bike off the shoulder and start making some miles!
0 · Reply
SmartestMoney
SmartestMoney Jun. 18 at 6:56 PM
0 · Reply
50bps
50bps Jun. 18 at 6:56 PM
0 · Reply
Strangperson
Strangperson Jun. 18 at 4:12 PM
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 16 at 6:58 PM
$SPRB i'm posting this here and here only $BCYC negative EV a whole bunch of programs (check their website) baker brothers bought in at much higher prices felix baker taking over as chairman today do your own research I added today
5 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 11 at 7:23 PM
$BCYC still a chance to buy under 9 anyone interested ?
1 · Reply
SmartestMoney
SmartestMoney Jun. 11 at 3:20 PM
$BCYC Do it
1 · Reply
SmartestMoney
SmartestMoney Jun. 6 at 2:50 PM
$BCYC 👁️👁️
0 · Reply
50bps
50bps Jun. 6 at 2:46 PM
$BCYC gettign tight. ht @SmartestMoney
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jun. 4 at 3:35 PM
$BCYC Am I the only one who thinks there is a TON of hidden value here at 8 dollars and change the market for this name is very thin, but it just makes the current trading price almost meaningless Bakers and others are in much higher a piece of good news could have this 100% up inside of a day
0 · Reply
GoImugene
GoImugene Jun. 3 at 5:51 PM
$BCYC Nectin-4 BTC (Bicycle Toxin Conjugate) which is basically an ADC, had decent results in 1st line cisplatin ineligible patients. As of 3 Jan 2025, 22 pts were enrolled from Nov 2023 to Jul 2024 with a median time on treatment of 22.9 weeks and 12 pts still receiving study treatment. Median age was 77 years; 46% of pts had an ECOG performance status (PS) of 2; 55% with CrCl < 60 mL/min. With 20 efficacy evaluable pts, the ORR is 65.0% (95% CI, 40.8, 84.6), including 5 CRs (25.0%; 4 confirmed), 8 PRs (40.0%; 6 confirmed) and 5 SD (25.0%). Median follow-up was 7.1 mo (range 1.0 – 13.2) and median duration of response was not reached. DCR is 90.0%. The most common grade (Gr) ≥3 TRAEs included ALT increased and neutropenia (13.6% each), and diarrhea, asthenia, hypomagnesemia, and pneumonia (9.1% each). Serious TRAEs related to zele or zele + pembro occurred in 9.1%. Treatment-related peripheral neuropathy occurred in 50.0% (27.3% Gr1, 13.6% Gr2, 9.1% Gr3).
0 · Reply
SmartestMoney
SmartestMoney May. 30 at 1:38 PM
1 · Reply
Jabed206
Jabed206 May. 28 at 1:31 PM
$BCYC 42% down since start of year... well done..
0 · Reply
SmartestMoney
SmartestMoney May. 21 at 2:41 PM
$BCYC For the love of the lord… $10+ cash per share
0 · Reply
Christyalmond
Christyalmond May. 13 at 2:50 PM
$BCYC down 10% again?
0 · Reply
Armonica423
Armonica423 May. 7 at 2:05 AM
$BCYC CYDY
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT May. 6 at 6:47 PM
$BCYC picked some up in todays volatility
0 · Reply
JarvisFlow
JarvisFlow May. 6 at 2:23 PM
Morgan Stanley has updated their rating for Bicycle Therapeutics ( $BCYC ) to Equal-Weight with a price target of 17.
0 · Reply
JarvisFlow
JarvisFlow May. 2 at 4:02 PM
B. Riley Securities has updated their rating for Bicycle Therapeutics ( $BCYC ) to Neutral with a price target of 14.
0 · Reply
JarvisFlow
JarvisFlow May. 2 at 2:18 PM
JMP Securities has adjusted their stance on Bicycle Therapeutics ( $BCYC ), setting the rating to Market Outperform with a target price of 26 → 22.
0 · Reply
JarvisFlow
JarvisFlow May. 2 at 12:30 PM
Needham has updated their rating for Bicycle Therapeutics ( $BCYC ) to Buy with a price target of 29.
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 10:30 PM
Barclays has updated their rating for Bicycle Therapeutics ( $BCYC ) to Overweight with a price target of 15.
0 · Reply